Рекомендации по диагностике и лечению взрослых больных язвенным колитом



страница9/9
Дата01.05.2016
Размер0.52 Mb.
1   2   3   4   5   6   7   8   9

6. ПРОГНОЗ


Риск тяжелого обострения ЯК в течение жизни составляет 15%, при этом вероятность тяжелой атаки выше у больных с тотальным поражением толстой кишки. При проведении адекватной противорецидивной терапии в течение 5 лет обострений удается избежать у половины пациентов, а в течение 10 лет - у 20% больных. В течение первого года после постановки диагноза вероятность колэктомии составляет 4-9% (при тяжелой атаке - около 50%), в дальнейшем с каждым годом заболевания риск колэктомии увеличивается на 1%. Факторами риска агрессивного течения ЯК являются прогрессирование поражения от дистального (проктита) к тотальному, первичный склерозирующий холангит, а также детский и подростковый возраст на момент начала заболевания.
ИСПОЛЬЗОВАННАЯ ЛИТЕРАТУРА

i Гастроэнтерология. Национальное руководство / Под ред. В.Т. Ивашкина, Т.Л. Лапиной. ГЭОТАР Медиа, 2008. – 754 c.

ii Воробьев Г.И., Халиф И.Л. Неспецифические воспалительные заболевания кишечника. Миклош, М. 2008

iii Marchal J, Hilsden R. Environment and epidemiology of inflammatory bowel disease // in Inflammatory bowel disease. Ed. Satsangi J, Sutherland L – Churchill-Livingstone. – 2003. – 17-28

iv Irvine EJ, Farrokhyar F, Swarbick ET. Z critical review of epidemiological studies in inflammatory bowel disease. Scand. J. Gastroenterol. 2001. 36(1): 2-15

v OCEBM Levels of Evidence Working Group. "The Oxford 2011 Levels of Evidence". Oxford Centre for Evidence-Based Medicine.

vi Dignass A, et al, Second EUROPEAN evidence-based Consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosis, Journal of Crohn's and Colitis (2012)

vii Travis SP, Dinesen L. Remission in trials of ulcerative colitis: what does it mean? Pract Gastroenterol 2010;30:17–20.

viii D'Haens G, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 2007;132:763–86

ix Katsanos KH, Vermeire S, Christodoulou DK, Riis L, Wolters F, Odes S, et al. Dysplasia and cancer in inflammatory bowel disease 10 years after diagnosis: results of a population-based European collaborative follow-up study. Digestion 2007;75: 113–21.

x Silverberg MS, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005;19(Suppl A):5–36.

xi Truelove SC et al. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 1955;2:1041–8.

xii Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987;317:1625–9.

xiii Чашкова Е.Ю., Владимирова А.А., Неустроев В.Г. и др.. Воспалительные заболевания толстой кишки - аспекты диагностики. Бюллетень Восточно-Сибирского научного центра СО РАМН. 2011. № 4-2. С. 209-221.

xiv Григорьева Г.А., Мешалкина Н.Ю. О проблеме системных проявлений воспалительных заболеваний кишечника. Фарматека. 2011. № 15. С. 44-49

xv Issa M, Vikayapal A, Gracham MB et al. Impact of Clostridium difficile in inflammatory bowel disease patients. Clin Gastroenterol Hepatol 2007; 5: 345-351

xvi Rodeman JF, Dubberke ER, Reske KA et al. Incidence of Clostridium difficile in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2007; 5: 339-344

xvii Issa M, Ananthakrishnan AN, Binion DG. Clostridium difficile and inflammatory bowel disease. Inflamm Bowel Dis. 2008; 14:1432-42

xviii Nguyen GC, Kaplan GG, Harris ML et al. A national survey of the prevalence and impact of Clostridium difficile infection among hospitalized inflammatory bowel disease patients. Am J Gastroenterol. 2008; 103: 1443-50

xix Mindenmark M, Larsson A. Rulling out IBD estimation of the possible economic effects of pre-endoscopic screening with F-calprotectin. Clin Biochem 2012; 45: 552-5

xx Costa F, Mumolo MG, Bellini M, Romano MR, Ceccarelli L, Arpe P, et al. Role of faecal calprotectin as non-invasive marker of intestinal inflammation. Dig Liver Dis 2003;35:642–7.

xxi Корнеева О.И., Ивашкин В.Т. Антибиотикоассоциированный колит: патоморфология, клиника, лечение. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2007. Т. 17. № 3. С. 65-71

xxii Ивашкин В.Т., Шептулин А.А., Шифрин О. С., Галимова С.Ф., Юрманова Е.Н. Vикроскопический колит: клинические формы, диагностика, лечение. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2006. Т.16, №6. С. 56-60

xxiii Голованчикова В.М., Шифрин О.С., Ивашкин В.Т. Современные подходы к лечению хронических воспалительных заболеваний кишечника. Рос. мед. вести. 2009. Т. 14, № 3. С. 29–37

xxiv Белоусова Е.А., Никитина Н.В., Цодикова О.М.. Лечение язвенного колита легкого и среднетяжелого течения. Фарматека. 2013. № 2. С. 42-46

xxv Халиф И.Л. Лечебная тактика при язвенном колите. Российский журнал гастроэнтерологии, гепатологии, колопроктологии, 2006. Т16. №3. С. 58-62

xxvi Dignass A, et al, Second EUROPEAN evidence-based Consensus on the diagnosis and management of ulcerative colitis: Current management, Journal of Crohn's and Colitis (2012).

xxvii Халиф И.Л. Принципы лечения язвенного колита (рекомендации российской группы по изучению воспалительных заболеваний кишечника). Колопроктология, 2006(2): с.31-33

xxviii Su C, Lewis JD, Goldberg B, Brensinger C, Lichtenstein GR. A meta-analysis of the placebo rates of remission and response in clinical trials of active ulcerative colitis. Gastroenterology 2007;132:516–26.

xxix Marshall JK, Thabane M, Steinhart AH, Newman JR, Anand A, Irvine EJ. Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2010 [CD004115-CD004115].

xxx Marshall JK, Irvine EJ. Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis. Gut 1997;40: 775–81.

xxxi Lamet M. A multicenter, randomized study to evaluate the efficacy and safety of mesalamine suppositories 1 g at bedtime and 500 mg twice daily in patients with active mild-to-moderate ulcerative proctitis. Dig Dis Sci 2011;56:513–22

xxxii Safdi M, DeMicco M, Sninsky C, Banks P, Wruble L, Deren J, et al. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol 1997;92:1867–71.

xxxiii Sutherland L, Macdonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2006:CD000543.

xxxiv Regueiro M, Loftus Jr EV, Steinhart AH, Cohen RD. Medical management of left-sided ulcerative colitis and ulcerative proctitis: critical evaluation of therapeutic trials. Inflamm Bowel Dis 2006;12:979–94.

xxxv Ford AC, Achkar J-P, Khan KJ, Kane SV, Talley NJ, Marshall JK, et al. Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol 2011;106:601–16.

xxxvi Kane SV, Bjorkman DJ. The efficacy of oral 5-ASAs in the treatment of active ulcerative colitis: a systematic review. Rev Gastroenterol Disord 2003;3:210–8.

xxxvii Ford AC, Achkar J-P, Khan KJ, Kane SV, Talley NJ, Marshall JK, et al. Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol 2011;106:601–16.

xxxviii Kane SV, Bjorkman DJ. The efficacy of oral 5-ASAs in the reatment of active ulcerative colitis: a systematic review. Rev Gastroenterol Disord 2003;3:210–8.

xxxix Sutherland L, Macdonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2006:CD000543.

xl Gisbert JP, Linares PM, McNicholl AG, Mate J, Gomollon F. Meta-analysis: the efficacy of azathioprine and mercaptopurine in ulcerative colitis. Aliment Pharmacol Ther 2009;30:126–37.

xli Panaccione R, Ghosh S, Middleton S, et al. Infliximab, azathioprine or infliximab + azathioprine for treatment of moderate to severe ulcerative colitis. The UC SUCCESS trial. J Crohns Colitis 2011;5:13.

xlii Gonzalez-Huix F, Fernandez-Banares F, Esteve-Comas M, Abad-Lacruz A, Cabre E, Acero D, et al. Enteral versus parenteral nutrition as adjunct therapy in acute ulcerative colitis. Am J Gastroenterol 1993;88:227–32

xliii Khan KJ, Ullman TA, Ford AC, Abreu MT, Abadir A, Abadir A, et al. Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol 2011;106:661–73.

xliv Ohkusa T, Kato K, Terao S, Chiba T, Mabe K, Murakami K, et al. Newly developed antibiotic combination therapy for ulcerative

colitis: a double-blind placebo-controlled multicenter trial. Am J Gastroenterol 2010;105:1820–9.



xlv Järnerot G, Hertervig E, Friis-Liby I, Blomquist L, Karlen P, Granno C, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005;128:1805–11.

xlvi Lees CW, Heys D, Ho GT, Noble CL, Shand AG, Mowat C, et al. A retrospective analysis of the efficacy and safety of infliximab as rescue therapy in acute severe ulcerative colitis. Aliment Pharmacol Ther 2007;26:411–9.

xlvii Van Assche G, D'Haens G, Noman M, Vermeire S, Hiele M, Asnong K, et al. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology 2003;125:1025–31.

xlviii Sjoberg M, Walch A, Meshkat M, Gustavsson A, Jarnerot G, Vogelsang H, et al. Infliximab or cyclosporine as rescue therapy in hospitalized patients with steroid-refractory ulcerative colitis: a retrospective observational study. Inflamm Bowel Dis 2012; 18(2), p.212-8.

xlix Sokol H, Seksik P, Carrat F, Nion-Larmurier I, Vienne A, Beaugerie L, et al. Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy. Gut 2010;59:1363–8.

l Reinisch W, Sandborn WJ, Rutgeerts P, Feagan BG, Rachmilewitz D, Hanauer SB, et al. Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studies. Inflamm Bowel Dis 2012;18:201–11.

li Chebli LA, LDdM Chaves, Pimentel FF, Guerra DM, RMdF Barros, Gaburri PD, et al. Azathioprine maintains long-term steroid-free remission through 3 years in patients with steroid-dependent ulcerative colitis. Inflamm Bowel Dis 2010;16:613–9.

lii Randall JSB, Warren BF, Travis SP, Mortensen NJ, George BD. Delayed surgery for acute severe colitis is associated with increased risk of postoperative complications. Br J Surg 2010;97: 404–9

liii Lennard-Jones JE, Ritchie JK, Hilder W, Spicer CC. Assessment of severity in colitis: a preliminary study. Gut 1975;16:579–84

liv Travis SP, Farrant JM, Ricketts C, Nolan DJ, Mortensen NM, Kettlewell MG, et al. Predicting outcome in severe ulcerative colitis. Gut 1996;38:905–10

lv Lindgren SC, Flood LM, Kilander AF, Lofberg R, Persson TB, Sjodahl RI. Early predictors of glucocorticosteroid treatment failure in severe and moderately severe attacks of ulcerative colitis. Eur J Gastroenterol Hepatol 1998;10:831–5

lvi Benazzato L, D'Inca R, Grigoletto F, Perissinotto E, Medici V, Angriman I, et al. Prognosis of severe attacks in ulcerative colitis: effect of intensive medical treatment. Dig Liver Dis 2004;36:461–6

lvii Almer S, Bodemar G, Franzen L, Lindstrom E, Nystrom P, Strom M. Use of air enema radiography to assess depth of ulceration during acute attacks of ulcerative colitis. Lancet 1996;347: 1731–5.

lviii Carbonnel F, Lavergne A, Lemann M, Bitoun A, Valleur P, Hautefeuille P, et al. Colonoscopy of acute colitis. A safe and reliable tool for assessment of severity. Dig Dis Sci 1994;39: 1550–7.

lix Ferrante M, Vermeire S, Katsanos KH. Predictors of early response to infliximab in patients with ulcerative colitis. Inflamm Bowel Dis. 2007 Feb;13(2):123-8.

lx Gonzalez-Lama Y, Fernandez-Blanco I, Lopez-SanRoman A. Open-label infliximab therapy in ulcerative colitis: a multicenter survey of results and predictors of response. Hepatogastroenterology. 2008 Sep-Oct;55(86-87):1609-14.

lxi Fasanmade AA, Adedokun OJ, Olson A, Strauss R, Davis HM. Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis. Int J Clin Pharmacol Ther. 2010 May;48(5):297-308.

lxii Oussalah A, Evesque L, Laharie D, Roblin X. A multicenter experience with infliximab for ulcerative colitis: outcomes and predictors of response, optimization, colectomy, and hospitalization. Am J Gastroenterol. 2010 Dec;105(12):2617-25

lxiii А.О. Головенко, И.Л. Халиф, О.В. Головенко, В.В. Веселов. Предикторы эффективности инфликсимаба у больных с тяжелой атакой язвенного колита. Российский журнал гастроэнтерологии, гепатологии, колопроктологии, 2013. 3.

lxiv American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: controlling tuberculosis in the United States. Am J Respir Crit Care Med, 2005. 172(9): p. 1169-227.

lxv Rahier, J.F., et al., European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis, 2009. 3(2): p. 47-91

lxvi Ardizzone S, Maconi G, Russo A, Imbesi V, Colombo E, Bianchi PG. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut 2006;55:47–53

lxvii Panaccione R, Ghosh S, Middleton S, et al. Infliximab, azathioprine or infliximab + azathioprine for treatment of moderate to severe ulcerative colitis. The UC SUCCESS trial. J Crohns Colitis 2011;5:13.

lxviii Van Assche G, D'Haens G, Noman M, Vermeire S, Hiele M, Asnong K, et al. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology 2003;125:1025–31.

lxix Van Assche G, D'Haens G, Noman M, Vermeire S, Hiele M, Asnong K, et al. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology 2003;125:1025–31.

lxx Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001;48:526–35

lxxi Jess T, Loftus Jr EV, Velayos FS, Harmsen WS, Zinsmeister AR, Smyrk TC, et al. Risk of intestinal cancer in inflammatory bowel disease: a population-based study from olmsted county, Minnesota. Gastroenterology 2006;130:1039–46

lxxii Bergeron V, Vienne A, Sokol H, Seksik P, Nion-Larmurier I, Ruskone-Fourmestraux A, et al. Risk factors for neoplasia in inflammatory bowel disease patients with pancolitis. Am J Gastroenterol 2010, [advance online publication, 15 June 2010]

lxxiii Rutter M, Saunders B, Wilkinson K, Rumbles S, Schofield G, Kamm M, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 2004;126:451–9

lxxiv Справочник по колопроктологии под редакцией проф. Ю.А. Шелыгина, проф Л.А. Благодарного: 2012. «Литтерра», с.460-522.

lxxv Travis SPL, Farrant JM, Ricketts C, et al. Predicting outcome in severe ulcerative colitis // Gut 1996;38:905—10.

lxxvi Richards DM, Hughes SA, Irving MH, Scott NA. Patient quality of life after successful restorative proctocolectomy is normal. Colorectal Dis 2001;3:223–6.

lxxvii McLaughlin SD, Clark SK, Thomas-Gibson S, Tekkis P, Ciclitira PJ, Nicholls RJ. Guide to endoscopy of the ileo-anal pouch following restorative proctocolectomy with ileal pouch-anal anastomosis; indications, technique, and management of common findings. Inflamm Bowel Dis 2009;15:1256–63.

lxxviii Berndtsson I, Oresland T. Quality of life before and after proctocolectomy and IPAA in patients with ulcerative proctocolitis—a prospective study. Colorectal Dis 2003;5:173–9

lxxix Marcello PW, Roberts PL, Schoetz Jr DJ, Coller JA, Murray JJ, Veidenheimer MC. Long-term results of the ileoanal pouch procedure. Arch Surg 1993;128:500–3 [discussion 503–4]

lxxx Sagar PM, Pemberton JH. Ileo-anal pouch function and dysfunction. Dig Dis 1997;15:172–88.

lxxxi Meagher AP, Farouk R, Dozois RR, Kelly KA, Pemberton JH. J ileal pouch-anal anastomosis for chronic ulcerative colitis: complications and long-term outcome in 1310 patients. Br J Surg 1998;85:800–3.

lxxxii Setti-Carraro P, Ritchie JK, Wilkinson KH, et al. The first 10 years’ experience of restorative proctocolectomy for ulcerative colitis. Gut. 1994;35:1070–1075

lxxxiii Fazio VW, Ziv Y, Church JM, et al. Ileal pouch-anal anastomoses complications and function in 1005 patients. Ann Surg. 1995;222:120–127

lxxxiv Belliveau P, Trudel J, Vasilevsky CA, et al. Ileoanal anastomosis with reservoirs: complications and long-term results. Can J Surg. 1999;42: 345–352

lxxxv Pinto RA, Canedo J, Murad-Regadas S, Regadas SF, Weiss EG, Wexner SD. Ileal pouch-anal anastomosis in elderly patients: is there a difference in morbidity compared with younger patients? Colorectal Dis 2011;13:177–83

lxxxvi Church JM. Functional outcome and quality of life in an elderly patient with an ileal pouch-anal anastomosis: a 10-year follow up. Aust N Z J Surg 2000;70:906–7

lxxxvii Chapman JR, Larson DW, Wolff BG, Dozois EJ, Cima RR, Pemberton JH, et al. Ileal pouch-anal anastomosis: does age at the timeof surgery affect outcome? Arch Surg 2005;140:534–40

lxxxviii Delaney CP, Dadvand B, Remzi FH, Church JM, Fazio VW. Functional outcome, quality of life, and complications after ileal pouch-anal anastomosis in selected septuagenarians. Dis Colon Rectum 2002;45:890–4.

lxxxix Olsen KO, Joelsson M, Laurberg S, Oresland T. Fertility after ileal pouch-anal anastomosis in women with ulcerative colitis. Br J Surg 1999;86:493–5.

xc Ording OK, Juul S, Berndtsson I, Oresland T, Laurberg S. Ulcerative colitis: female fecundity before diagnosis, during disease, and after surgery compared with a population sample. Gastroenterology 2002;122:15–9.

xci Gorgun E, Remzi FH, Goldberg JM, Thornton J, Bast J, Hull TL, et al. Fertility is reduced after restorative proctocolectomy with ileal pouch anal anastomosis: a study of 300 patients. Surgery 2004;136:795–803.

xcii Johnson P, Richard C, Ravid A, Spencer L, Pinto E, Hanna M, et al. Female infertility after ileal pouch-anal anastomosis for ulcerative colitis. Dis Colon Rectum 2004;47:1119–26.

xciii Oresland T, Palmblad S, Ellstrom M, Berndtsson I, Crona N, Hulten L. Gynaecological and sexual function related to anatomical changes in the female pelvis after restorative proctocolectomy. Int J Colorectal Dis 1994;9:77–81.

xciv Alves A, Panis Y, Bouhnik Y, Maylin V, Lavergne-Slove A, Valleur P. Subtotal colectomy for severe acute colitis: a 20-year experience of a tertiary care center with an aggressive and early surgical policy. J Am Coll Surg 2003;197:379–85

xcv Berg DF, Bahadursingh AM, Kaminski DL, Longo WE. Acute surgical emergencies in inflammatory bowel disease. Am J Surg 2002;184:45–51.

xcvi Hyman NH, Cataldo P, Osler T. Urgent subtotal colectomy for severe inflammatory bowel disease. Dis Colon Rectum 2005;48: 70–3.

xcvii Holubar SD, Larson DW, Dozois EJ, Pattana-Arun J, Pemberton JH, Cima RR. Minimally invasive subtotal colectomy and ileal pouch-anal anastomosis for fulminant ulcerative colitis: a reasonable approach? Dis Colon Rectum 2009;52:187–92.

xcviii Marceau C, Alves A, Ouaissi M, Bouhnik Y, Valleur P, Panis Y. Laparoscopic subtotal colectomy for acute or severe colitis complicating inflammatory bowel disease: a case-matched study in 88 patients. Surgery 2007;141:640

xcix Annibali R, Oresland T, Hulten L. Does the level of stapled ileoanal anastomosis influence physiologic and functional outcome? Dis Colon Rectum 1994;37:321–9.

c Burns EM, Bottle A, Aylin P, Clark SK, Tekkis P, Darzi A, et al. Volume analysis of outcome following restorative proctocolectomy. Br J Surg 2011;98:408–17.

ci Tekkis PP, Fazio VW, Lavery IC, Remzi FH, Senagore AJ, Wu JS, et al. Evaluation of the learning curve in ileal pouch-anal anastomosis surgery. Ann Surg 2005;241:262–8.

cii Lepisto A, J. JH.. Fate of the rectum after colectomy with ileorectal anastomosis in ulcerative colitis. Scand J Surg 2005;94:40–2

ciii Burns EM, Bottle A, Aylin P, Clark SK, Tekkis P, Darzi A, et al. Volume analysis of outcome following restorative proctocolectomy. Br J Surg 2011;98:408–17.

civ Burns EM, Bottle A, Aylin P, Clark SK, Tekkis P, Darzi A, et al. Volume analysis of outcome following restorative proctocolectomy. Br J Surg 2011;98:408–17

cv Edwards, C.M., B. George, and B.F. Warren, Diversion colitis: new light through old windows. Histopathology, 1999. 35(1): p. 86-7.

cvi Annibali R, Oresland T, Hulten L. Does the level of stapled ileoanal anastomosis influence physiologic and functional outcome? Dis Colon Rectum 1994;37:321–9

cvii Shepherd NA, Jass JR, Duval I, Moskowitz RL, Nicholls RJ, Morson BC. Restorative proctocolectomy with ileal reservoir: pathological and histochemical study of mucosal biopsy specimens. J Clin Pathol 1987;40:601–7.

cviii Setti Carraro PG, Talbot IC, Nicholls JR. Patterns of distribution of endoscopic and histological changes in the ileal reservoir after restorative proctocolectomy for ulcerative colitis. A long-term follow-up study. Int J Colorectal Dis 1998;13:103–7.

cix Ferrante M, D'Hoore A, Vermeire S, et al. Corticosteroids but not infliximab increase short-term postoperative infectious complications in patients with ulcerative colitis. Inflamm Bowel Dis 2009;15:1062–70.

cx Lake JP, Firoozmand E, Kang JC, Vassiliu P, Chan LS, Vukasin P, et al. Effect of high-dose steroids on anastomotic complications after proctocolectomy with ileal pouch-anal anastomosis. J Gastrointest Surg 2004;8:547–51.

cxi Mahadevan U, Loftus Jr EV, TremaineWJ, Pemberton JH, Harmsen WS, Schleck CD, et al. Azathioprine or 6-mercaptopurine before colectomy for ulcerative colitis is not associated with increased postoperative complications. Inflamm Bowel Dis 2002;8:311–6.

cxii Pugliese D, Armuzzi A, Rizzo G, et al. Effect of anti-TNF-alpha treatment on short-term post-operative complications in patients with inflammatory bowel disease. Gut 2010;59(Suppl III):A13

cxiii Subramanian V, Pollok RC, Kang JY, Kumar D. Systematic review of postoperative complications in patients with inflammatory bowel disease treated with immunomodulators. Br J Surg 2006;93:793–9

cxiv Meta-analysis: effect of preoperative infliximab use on early postoperative complications in patients with ulcerative colitis undergoing abdominal surgery. Yang Z, Wu Q, Wang F, Wu K, Fan D. Aliment Pharmacol Ther. 2012 Nov;36(10):922-8. doi: 10.1111/apt.12060. Epub 2012 Sep 24.

cxv Dignass, A., et al., Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis, 2012. 6(10): p. 991-1030.

cxvi Meagher AP, Farouk R, Dozois RR, Kelly KA, Pemberton JH. J ileal pouch-anal anastomosis for chronic ulcerative colitis: complications and long-term outcome in 1310 patients. Br J Surg 1998;85:800–3.

cxvii Simchuk EJ, Thirlby RC. Risk factors and true incidence of pouchitis in patients after ileal pouch-anal anastomoses. World J Surg 2000;24:851–6

cxviii Stahlberg D, Gullberg K, Liljeqvist L, Hellers G, Lofberg R. Pouchitis following pelvic pouch operation for ulcerative colitis. Incidence, cumulative risk, and risk factors. Dis Colon Rectum 1996;39:1012–8.

cxix Penna C, Tiret E, Kartheuser A, Hannoun L, Nordlinger B, Parc R. Function of ileal J pouch-anal anastomosis in patients with familial adenomatous polyposis. Br J Surg 1993;80:765–7

cxx Tjandra JJ, Fazio VW, Church JM, Oakley JR, Milsom JW, Lavery IC. Similar functional results after restorative proctocolectomy in patients with familial adenomatous polyposis and mucosal ulcerative colitis. Am J Surg 1993;165:322–5

cxxi Shen B, Achkar JP, Lashner BA. Irritable pouch syndrome: a new category of diagnosis for symptomatic patients with ileal pouch-anal anastomosis. Am J Gastroenterol. 2002 Apr;97(4):972-7.


Каталог: sites -> default -> files -> 2015
2015 -> Российская гастроэнтерологическая ассоциация пищевод баррета
2015 -> Российская гастроэнтерологическая ассоциация гастроэзофагеальная рефлюксная болезнь
2015 -> 2. виды, условия и формы оказания медицинской помощи
2015 -> Рабочая программа по дисциплине "Акушерство и гинекология" цикла С. 3 "Акушерство и гинекология" для специальности
2015 -> Диагностика и лечение хронической ишемической болезни сердца
2015 -> Уровень Доказательная база


Поделитесь с Вашими друзьями:
1   2   3   4   5   6   7   8   9


База данных защищена авторским правом ©zodorov.ru 2017
обратиться к администрации

    Главная страница